PubMed:25097285 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":286,"end":293},"obj":"HP_0000739"},{"id":"T2","span":{"begin":326,"end":336},"obj":"HP_0000716"}],"text":"Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.\nAIM: Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are effective in treating anxiety disorders associated with major depressive disorder (MDD). This randomized, controlled, parallel-group, open-label, phase 4 trial (CTRI/2012/08/002895) was undertaken to compare the effectiveness and safety of desvenlafaxine versus escitalopram, a standard antidepressant.\nMATERIALS AND METHODS: Effectiveness was assessed using the Hamilton Depression Rating Scale (HAM-D17) and Hamilton Anxiety Rating Scale (HAM-A). Response to treatment was assessed by ≥50% decrease of baseline scores (responder rate). Safety and tolerability was evaluated by changes in routine laboratory parameters, vital signs, and adverse events reported by the subject and/or observed by the clinician.\nRESULTS: Responder rates for both HAM-A and HAM-D scores at 8 weeks were better in the escitalopram group compared to the desvenlafaxine group (HAM-A 76.92% vs. 71.05%; HAM-D 79.48% vs 73.68%) but the differences were not statistically significant (P = 0.59 and P = 0.61). Within group changes of both scores, from baseline to subsequent visits in both treatment arms were statistically significant (P \u003c 0.01).\nCONCLUSION: The effectiveness of desvenlafaxine was comparable to escitalopram, but escitalopram was better tolerated."}

{"project":"NEUROSES","denotations":[{"id":"T1","span":{"begin":37,"end":49},"obj":"CHEBI_36791"},{"id":"T2","span":{"begin":526,"end":538},"obj":"CHEBI_36791"},{"id":"T3","span":{"begin":1062,"end":1074},"obj":"CHEBI_36791"},{"id":"T4","span":{"begin":1452,"end":1464},"obj":"CHEBI_36791"},{"id":"T5","span":{"begin":1470,"end":1482},"obj":"CHEBI_36791"},{"id":"T6","span":{"begin":54,"end":68},"obj":"CHEBI_83527"},{"id":"T7","span":{"begin":504,"end":518},"obj":"CHEBI_83527"},{"id":"T8","span":{"begin":1097,"end":1111},"obj":"CHEBI_83527"},{"id":"T9","span":{"begin":1419,"end":1433},"obj":"CHEBI_83527"},{"id":"T10","span":{"begin":123,"end":127},"obj":"PATO_0000610"},{"id":"T11","span":{"begin":398,"end":402},"obj":"PATO_0000610"},{"id":"T12","span":{"begin":128,"end":133},"obj":"CHEBI_35209"},{"id":"T13","span":{"begin":403,"end":408},"obj":"CHEBI_35209"},{"id":"T14","span":{"begin":167,"end":176},"obj":"CHEBI_28790"},{"id":"T15","span":{"begin":208,"end":217},"obj":"CHEBI_28790"},{"id":"T16","span":{"begin":167,"end":176},"obj":"CHEBI_350546"},{"id":"T17","span":{"begin":208,"end":217},"obj":"CHEBI_350546"},{"id":"T18","span":{"begin":186,"end":196},"obj":"CHEBI_35222"},{"id":"T19","span":{"begin":198,"end":202},"obj":"CHEBI_50949"},{"id":"T22","span":{"begin":347,"end":350},"obj":"CHEBI_566274"},{"id":"T23","span":{"begin":391,"end":396},"obj":"CHEBI_24433"},{"id":"T24","span":{"begin":1075,"end":1080},"obj":"CHEBI_24433"},{"id":"T25","span":{"begin":1112,"end":1117},"obj":"CHEBI_24433"},{"id":"T26","span":{"begin":1255,"end":1260},"obj":"CHEBI_24433"},{"id":"T27","span":{"begin":410,"end":415},"obj":"PATO_0000083"},{"id":"T28","span":{"begin":551,"end":565},"obj":"CHEBI_35469"},{"id":"T30","span":{"begin":795,"end":799},"obj":"PATO_0001470"},{"id":"T31","span":{"begin":795,"end":799},"obj":"PATO_0000161"},{"id":"T32","span":{"begin":84,"end":94},"obj":"PM3425"},{"id":"T33","span":{"begin":636,"end":646},"obj":"PM3425"},{"id":"T34","span":{"begin":84,"end":94},"obj":"PM3425"},{"id":"T35","span":{"begin":636,"end":646},"obj":"PM3425"}],"text":"Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.\nAIM: Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are effective in treating anxiety disorders associated with major depressive disorder (MDD). This randomized, controlled, parallel-group, open-label, phase 4 trial (CTRI/2012/08/002895) was undertaken to compare the effectiveness and safety of desvenlafaxine versus escitalopram, a standard antidepressant.\nMATERIALS AND METHODS: Effectiveness was assessed using the Hamilton Depression Rating Scale (HAM-D17) and Hamilton Anxiety Rating Scale (HAM-A). Response to treatment was assessed by ≥50% decrease of baseline scores (responder rate). Safety and tolerability was evaluated by changes in routine laboratory parameters, vital signs, and adverse events reported by the subject and/or observed by the clinician.\nRESULTS: Responder rates for both HAM-A and HAM-D scores at 8 weeks were better in the escitalopram group compared to the desvenlafaxine group (HAM-A 76.92% vs. 71.05%; HAM-D 79.48% vs 73.68%) but the differences were not statistically significant (P = 0.59 and P = 0.61). Within group changes of both scores, from baseline to subsequent visits in both treatment arms were statistically significant (P \u003c 0.01).\nCONCLUSION: The effectiveness of desvenlafaxine was comparable to escitalopram, but escitalopram was better tolerated."}

{"project":"Allie","denotations":[{"id":"SS1_25097285_2_0","span":{"begin":157,"end":196},"obj":"expanded"},{"id":"SS2_25097285_2_0","span":{"begin":198,"end":202},"obj":"abbr"},{"id":"SS1_25097285_2_1","span":{"begin":208,"end":252},"obj":"expanded"},{"id":"SS2_25097285_2_1","span":{"begin":254,"end":258},"obj":"abbr"},{"id":"SS1_25097285_2_2","span":{"begin":320,"end":345},"obj":"expanded"},{"id":"SS2_25097285_2_2","span":{"begin":347,"end":350},"obj":"abbr"},{"id":"SS1_25097285_5_0","span":{"begin":674,"end":703},"obj":"expanded"},{"id":"SS2_25097285_5_0","span":{"begin":705,"end":710},"obj":"abbr"}],"relations":[{"id":"AE1_25097285_2_0","pred":"abbreviatedTo","subj":"SS1_25097285_2_0","obj":"SS2_25097285_2_0"},{"id":"AE1_25097285_2_1","pred":"abbreviatedTo","subj":"SS1_25097285_2_1","obj":"SS2_25097285_2_1"},{"id":"AE1_25097285_2_2","pred":"abbreviatedTo","subj":"SS1_25097285_2_2","obj":"SS2_25097285_2_2"},{"id":"AE1_25097285_5_0","pred":"abbreviatedTo","subj":"SS1_25097285_5_0","obj":"SS2_25097285_5_0"}],"text":"Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.\nAIM: Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are effective in treating anxiety disorders associated with major depressive disorder (MDD). This randomized, controlled, parallel-group, open-label, phase 4 trial (CTRI/2012/08/002895) was undertaken to compare the effectiveness and safety of desvenlafaxine versus escitalopram, a standard antidepressant.\nMATERIALS AND METHODS: Effectiveness was assessed using the Hamilton Depression Rating Scale (HAM-D17) and Hamilton Anxiety Rating Scale (HAM-A). Response to treatment was assessed by ≥50% decrease of baseline scores (responder rate). Safety and tolerability was evaluated by changes in routine laboratory parameters, vital signs, and adverse events reported by the subject and/or observed by the clinician.\nRESULTS: Responder rates for both HAM-A and HAM-D scores at 8 weeks were better in the escitalopram group compared to the desvenlafaxine group (HAM-A 76.92% vs. 71.05%; HAM-D 79.48% vs 73.68%) but the differences were not statistically significant (P = 0.59 and P = 0.61). Within group changes of both scores, from baseline to subsequent visits in both treatment arms were statistically significant (P \u003c 0.01).\nCONCLUSION: The effectiveness of desvenlafaxine was comparable to escitalopram, but escitalopram was better tolerated."}